Important announcement concerning Temple Health and Keystone First. Our provider agreement with Keystone First, is scheduled to end on July 31st. Learn about your options to continue receiving care at Temple Health.
Breadcrumb
- Home
- About Us
- R&D Alliances
- Technology Transfer
- Technology Licensing
- Animal & PDX Models
Animal & PDX Models
Technology Transfer Contacts
- Inna Khartchenko, MS, MBA
Director, Technology Transfer
215-214-3989
[email protected] - Natalia Shalginskikh, PhD
Licensing Associate,
Technology Transfer
267-963-7121
[email protected] - Tatiana Venkova, PhD
Licensing Associate,
Technology Transfer
215-983-0257
[email protected]
(technologies available for licensing)
Note: Links to Patents may require a browser newer than Internet Explorer 9, such as Chrome, Safari, Firefox, Edge, or Internet Explorer 11
TECH ID | TITLE | LEAD INVENTOR | CONTACT |
---|---|---|---|
02-20 |
Tg-MISIIR-TAg transgenic mice: a model of epithelial ovarian |
Denise Connolly |
|
03-39R |
Ovarian Cancer Prone Mice: TgMISIIR -TAg-DR26 |
Denise Connolly |
|
06-34 |
Mouse model of Spontaneous Mesothelioma (Conditional Bap1 knockout mice) |
Joseph Testa |
|
06-37 |
Pak-1-KO mouse |
Jonathan Chernoff |
|
07-04 |
TgMISIIR-TAg-EE73 mice |
Denise Connolly |
|
98-12 |
PAK2 fl/fl Mouse |
Jonathan Chernoff |
|
99-19 |
Apc +/Min - FCCC mice: a model for colorectal cancer |
Margie Clapper |
|
211-JT |
Appl1 knock out mouse |
Joseph Testa |
|
223-GE |
TetO-p16 t Transgenic Mouse Allowing Inducible Expression of a Potent Cell Cycle Inhibitor |
Greg Enders |
|
261-JT |
Appl 1 FF mouse model |
Joseph Testa |
|
342-JC |
p21-Activated Kinase Inhibitor Domain Targeted Transgenic Mouse (ROSA26-LSL-PID) |
Jonathan Chernoff |
|
405-JC |
Mice with Transgene of iBox Peptide Inhibitor of Group B p21-Activated Kinases (ROSA26-LSL-iBox) |
Jonathan Chernoff |
|
448-DC |
TgMISIIR-TAg-DQ62 mice |
Denise Connolly |
|
472-NJ |
Brca1ΔC mouse with a new mutation in the Brca1 gene |
Neil Johnson |
|
475-WK |
Mouse Models of cystathionine beta-synthase (cbs) deficiency |
Warren Kruger |
|
513-JT |
Lck-MyrAkt2 transgenic mice. Mice with constitutively activate Akt2 expressed in immature thymic cells, which develop a high incidence of spontaneous thymic lymphomas |
Joseph Testa |
|
514-JT |
Lck-Dlx5 transgenic mice. Mice that over-express Dlx5 in immature thymic cells, which develop a high incidence of spontaneous thymic lymphomas. |
Joseph Testa |
|
515-JT |
Lck-MyrAkt2;Lck-Dlx5 mice. Mice with constitutively activate Akt2 and overexpression of Dlx5 in immature thymic cells, which develop a very high incidence of spontaneous thymic lymphomas. |
Joseph Testa |
|
523-DW |
H2t-/- mice |
David Wiest |
|
533-JT |
Tp53L/L:PtenL/L mouse model (conditional, with whole body homozygously floxed alleles of Tp53 and Pten) |
Joseph Testa |
Share
-
Share with Facebook
-
Share with twitter
-
Share with email
-
Print this